New drug aims to outsmart recurrent lymphoma
NCT ID NCT07187960
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests a new drug called TQB2825, a bispecific antibody that targets both CD3 and CD20 proteins, against standard immunotherapy for people with follicular lymphoma that has returned or not responded to treatment. About 228 participants will be randomly assigned to receive either TQB2825 or a combination of rituximab and chemotherapy. The main goal is to see if TQB2825 can delay cancer progression better than the current approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQB2825 injection (a bispecific antibody targeting CD3 and CD20)
What this could lead to
If it works, this could offer a new treatment option for people with follicular lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug may not be more effective than existing treatments and could have side effects like immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gansu Provincial Hospital
Lanzhou, Gansu, 730030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hainan General Hospital
Haikou, Hainan, 570311, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 301636, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linyi City People Hospital
Linyi, Shandong, 276000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
People's Hospital of Hunan Province
Changsha, Hunan, 410005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
People's Hospital of Tianjin
Tianjin, Tianjin Municipality, 300121, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, 830000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200023, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shengjing Hospital Of China Medical University
Shenyang, Liaoning, 110134, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yet-Sen University Cancer Certer
Guangzhou, Guangdong, 510700, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550004, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital Of Zhengzhou University
Zhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, 710061, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First People's Hospital Of Yunnan Province
Kunming, Yunnan, 650100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Hospital Of Dalian Medical University
Dalian, Liaoning, 116000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300308, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital of Tongji University
Shanghai, Shanghai Municipality, 200065, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yunan Cancer Hospital
Kunming, Yunnan, 650118, China
Contact Phone: •••-•••-•••• Email: •••••@•••••